Research - Jounce is developing an ILT4 antibody that can unleash the cancer killing effect of macrophages. Combining this checkpoint inhibitor with anti-PD-1 creates a two-pronged attack … Continue Reading
PremiumInsights - The prior email covered near-term 2021 catalysts for DCTH, CNCE and EPIX (HERE). The note below includes companies that we are watching with catalysts further out in 2021. Deeper dives … Continue Reading
PremiumResearch - Delcath (DCTH) is developing a drug/device combination product for the treatment of liver cancer that has metastasized from other parts of the body. The initial … Continue Reading
PremiumInsights - Tomorrow, Friday November 6, the FDA will hold an ADCOM for Biogen’s (BIIB) aducanumab. Aducanumab is a beta-amyloid drug for Alzheimer’s Disease that can receive … Continue Reading
PremiumInsights - Affimed’s (AFMD) ASH abstract for AFM13 was released today. The abstract (see here) covers AFM13 Phase 1 in relapsed/refractory CD30+ lymphoma patients. Affimed refers to this … Continue Reading
PremiumInsights - Earlier this week, Affimed announced a collaboration with Korean company NKMax to investigate the combination of AFM24, an EGFR engager, with autologous NK cell product … Continue Reading
PremiumResearch - Concert Pharma (CNCE) is developing a deuterated d-serine as an add-on therapy to existing schizophrenia treatments. In historical academic papers, d-serine has shown to enhance the NMDA … Continue Reading
Premium
